Table 1 Clinical features of AML patients according to DNMT3A R882 mutation status
Clinical features | Total (n = 870) | R882 wild-type (n = 796) | R882 mutation (n = 74) | P value |
|---|---|---|---|---|
Agea, years | 42 ± 15 | 41 ± 15 | 48 ± 11 | 6.64 × 10 −6 |
Age ≥ 60 years, n (%) | 103 (11.84) | 94 (11.81) | 9 (12.16) | 0.928 |
Male, n (%) | 476 (54.71) | 443 (55.65) | 33 (44.59) | 0.068 |
FAB classification, n (%) | ||||
 M2 | 445 (51.15) | 428 (53.77) | 17 (22.97) | 3.99 × 10 −7 |
 M4 | 180 (20.69) | 162 (20.35) | 18 (24.32) | 0.420 |
 M5 | 173 (19.89) | 139 (17.46) | 34 (45.95) | 4.31 × 10 −9 |
 Other subtypes or undetermined | 72 (8.28) | 67 (8.42) | 5 (6.76) |  |
Parameters at diagnosisa | ||||
 WBC count, ×109/L | 39.19 ± 62.25 | 37.56 ± 62.48 | 56.72 ± 57.27 | 0.012 |
 RBC count, ×1012/L | 2.32 ± 1.53 | 2.32 ± 1.58 | 2.25 ± 0.66 | 0.710 |
 Hemoglobin, g/L | 73.48 ± 21.11 | 73.45 ± 21.50 | 73.82 ± 16.36 | 0.858 |
 Platelets count, ×109/L | 58.21 ± 83.94 | 55.99 ± 84.15 | 82.71 ± 78.02 | 0.010 |
 Neutrophil count, ×109/L | 12.69 ± 32.04 | 12.53 ± 32.67 | 14.45 ± 24.10 | 0.630 |
 LDH, U/L | 555.17 ± 694.61 | 553.00 ± 713.95 | 578.29 ± 441.34 | 0.771 |
 Bone marrow blasts, % | 64.23 ± 21.40 | 63.97 ± 21.50 | 67.08 ± 20.19 | 0.244 |
Risk stratificationsb, n (%) | n = 759c | n = 696 | n = 63 |  |
 Intermediate risk | 384 (50.59) | 355 (51.01) | 29 (46.03) |  |
 Low risk | 202 (26.61) | 190 (27.30) | 12 (19.05) | 0.467d |
 High risk | 173 (22.79) | 151(21.70) | 22 (34.92) | 0.051d |
FLT3-ITD, n (%) | n = 733c | n = 670 | N = 63 |  |
 Negative | 637 (86.90) | 591 (88.21) | 46 (73.02) |  |
 Positive | 96 (13.10) | 79 (11.79) | 17 (26.98) | 0.001 |
Karyotype, n (%) | n = 789c | n = 721 | n = 68 |  |
 Normal cytogenetics | 479 (60.71) | 425 (58.95) | 54 (79.41) |  |
 Non-normal cytogenetics | 310 (39.29) | 296 (41.05) | 14 (20.59) | 0.001 |
HSCT, n (%) | 161 (18.51) | 151 (18.97) | 10 (13.51) | 0.248 |